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Record linkageObjective: To assess the long term effects of hypertensive disorders of pregnancy on renal function.
Design: Cohort study where exposure was gestational hypertension or preeclampsia in the first preg-
nancy. Normotensive women formed the comparison group.
Setting: Aberdeen, Scotland.
Participants: All women with date of birth on or before 30th June 1969 and at least their first singleton
delivery recorded in the Aberdeen Maternity and Neonatal Databank.
Methods: Participants were linked to the Renal Biochemistry Register, Scottish Morbidity Records,
Scottish Renal Registry and National Register for deaths.
Main outcome measures: Occurrence of chronic kidney disease (CKD) as identified from renal function
tests in later life, hospital admissions or death from kidney disease or recorded as receiving renal replace-
ment therapy.
Results: CKD was diagnosed in 7.5% and 5.2% of women who previously had GH and PE respectively com-
pared to 3.9% in normotensive women. The unadjusted odds ratio (95% confidence interval) of having
CKD in PE was 2.04 (1.53, 2.71) and that for GH was 1.37 (1.15, 1.65), while the adjusted odds ratio
(95% confidence interval) of CKD was 1.93 (1.44, 2.57) and 1.36 (1.13, 1.63) in women with PE and GH
respectively. Kaplan–Meier curves of survival time to development of chronic kidney disease revealed
that women with preeclampsia were susceptible to kidney function impairment earliest, followed by
those with gestational hypertension.
Conclusions: There was an increased subsequent risk of CKD associated with hypertensive disorders of
pregnancy. Women with GH and PE were also found to have CKD earlier than normotensive women.
 2016 The Authors. Published by Elsevier B.V. on behalf of International Society for the Study of
Hypertension in Pregnancy. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pre-eclampsia, the symptom complex of high blood pressure
and proteinuria, affects 4–8% of pregnancies [1]. It is a multi-
system disorder and its effects on subsequent cardiovascular
health of women [2,3] are well established. Pre-eclampsia is asso-
ciated with acute kidney function impairment [4,5] with recovery
typically occurring within six weeks of delivery of the baby. Rela-
tively little is known about the long term effects on the kidneyeither in terms of physical damage measured by albuminuria or
proteinuria, function impairment measured by reduction in
Glomerular Filtration Rate (GFR) or end stage kidney failure.
In their systematic review and meta-analysis, McDonald et al.
[6] identified 7 papers reporting on a total of 273 patients with
preeclampsia and less than 100 events of microalbuminuria.
Despite the limited numbers, they found evidence of an increased
risk of microalbuminuria following preeclampsia {pooled risk ratio
of 4.3 (95% CI 2.7, 6.9)} but there was considerable heterogeneity
among the included studies and a strong possibility of publication
bias. There was, however, no difference in terms of serum crea-
tinine levels and estimated Glomerular Filtration Rate (eGFR)
between women with preeclampsia and those without. An
updated search of the literature identified three additional papers
[7–9] all reporting a positive association between preeclampsia
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exposure and outcome measurement remained as did the possibil-
ity of publication bias. In their review, McDonald et al. [6] called for
further research investigating the persistence of microalbuminuria
following preeclampsia in larger population based studies,
taking into consideration confounding factors such as age, BMI,
smoking etc.
The overall aim of this research, was to assess the long term
effects of hypertensive disorders of pregnancy on kidney function
in, using a large phenotypically well-defined population based
cohort of women and adjusting for a large number of confounders.
In case of declining renal function, we also aimed to find out
whether there was a difference in the timing of onset of any decline.
2. Methods
2.1. Data sources and record linkage
The Aberdeen Maternity and Neonatal Databank (AMND),
started in 1950, is derived from the Aberdeen Maternity Hospital’s
obstetric records. Aberdeen Maternity Hospital is the only mater-
nity hospital in Aberdeen and serves as both a primary as well as
tertiary care unit. From the AMND, we identified a cohort of
women using the following inclusion and exclusion criteria:
2.1.1. Inclusion criteria
Primiparous mothers born on or before the 30th June 1969
(aged 40 years or over at the end date of the study period with a
singleton first delivery occurring at or beyond 20 weeks gestation
(including still births) and resident in the Grampian region.
2.1.2. Exclusion criteria
women with pre-existing chronic hypertension, kidney disease
as recorded in AMND by ICD-9 codes at the time of the first preg-
nancy; women who had twins or multiple foetuses in their first
pregnancy; women who were temporary residents, living in
Orkney or Shetland or elsewhere outside of the Grampian region
and women with any delivery with a gestation of less than
20 weeks were excluded from the cohort.
The following databases were linked to the AMND to derive
information on outcomes for the end of the study follow up period
– 31st July 2009:
(1) The Grampian Renal Biochemistry Dataset (GRBD) is an
existing extract of NHS Grampian’s Biochemistry Dataset
(1999–2009). All biochemistry services (in-patient, commu-
nity, private) in the Grampian region were provided by two
linked National External Quality Assessment Service moni-
tored laboratories. Data were extracted from the GRBD for
women in the AMND cohort who:
 had renal function tested at least one year after the date
of delivery
 were still living in the Grampian region after 1st July
1999
(2) The Scottish Morbidity Record for non-obstetric and non-
psychiatric general acute inpatient and day case discharges
from NHS hospitals in Scotland (SMR01) was introduced in
1961. This was used to identify any hospital admissions
from kidney diseases coded according to International Clas-
sification of Diseases (10th revision) codes.
(3) The Scottish Renal Registry (SRR) is a national registry of
patients on long term renal replacement therapy. All NHS
renal units contribute fully to this database. Data from Scot-
tish renal units were available from 1960 when regular and
routine renal replacement therapy (RRT) for end stage renal
disease (ESRD) started in Scotland.(4) National Records of Scotland (NRS) Data on Deaths (formerly
the General Register Office for Scotland (GROS)) – Data col-
lection in this register dates back to 1855. This register was
used to identify any deaths occurring in the cohort.
The AMND and GRBD datasets were linked by deterministic
matching of the Community Health Index (CHI) numbers, numbers
unique to patients registered with a general practice in Scotland.
CHI numbers of linked women were validated against the vital sta-
tus register to identify any deaths or migrations out of Grampian
region before 1st July 1999. Linkage of the AMND cohort to the
Scottish Morbidity Records (SMR01), death registrations (NR Scot-
land) and the Scottish Renal Registry was carried out by the Infor-
mation Services Division (ISD) of NHS Scotland using both
deterministic matching on CHI numbers and probability matching
using surname, initial of first name, date of birth and post code.
2.2. Study design
A cohort study design was used where women who had gesta-
tional hypertension (GH) or preeclampsia/ eclampsia (PE) as iden-
tified from the AMND formed the exposed cohort, while women
who were normotensive (NT) in their first pregnancy constituted
the comparison group.
2.3. Definition of exposure
Gestational hypertension and preeclampsia were defined
according to the criteria proposed by Davey and MacGillivray
[10] and used uniformly throughout the AMND. Gestational hyper-
tension was defined as diastolic pressure greater than 90 mmHg on
two occasions at least four hours apart or a single reading of
>110 mmHg; from 20 weeks gestation onwards in a previously
normotensive woman. Pre-eclampsia was defined as gestational
hypertension plus at least one episode of proteinuria of
0.3 g/24 h. Eclampsia was defined clinically as convulsions occur-
ring in the presence of pre-eclampsia. In this analysis, women with
preeclampsia and eclampsia were considered together as one
group.
2.4. Outcomes
The main outcome of interest was chronic kidney disease
defined according to the NICE modified Kidney Disease Outcomes
Quality Initiative (KDOQI) definitions for the classification of
chronic kidney disease based on renal function measured by
glomerular filtration rate (GFR) [11]. Renal function was assessed
using serum creatinine values determined by the Jaffe method
traceable over time to the international gold standard isotope dilu-
tion mass spectrometry (IDMS) method. It was expressed as esti-
mated Glomerular Filtration Rate (eGFR) calculated using the
modified 4 variable Modification of Diet in Renal Disease (MDRD)
equation suitable for use with IDMS traceable creatinine values.
According to these criteria, chronic kidney disease was present if
eGFR <60 mL/min/1.73 m2 sustained for P90 days. Proteinuria, a
measure of renal damage, was defined using urinary protein crea-
tinine ratio (PCR) and albumin creatinine ratio (ACR) as per SIGN
guidelines [12] and classified as chronic if sustained forP90 days.
We defined women to have CKD if they met either of these criteria
in line with KDIGO stage CKD 1-5.
2.5. Statistical analysis
Baseline characteristics were examined for women with GH or
PE and compared with those who were normotensive (NT) in their
first pregnancy. Results were presented as means (and standard
346 D. Ayansina et al. / Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 6 (2016) 344–349deviation) for continuous variables and frequencies (and percent-
ages) for categorical variables. Pair-wise comparisons were done
using independent samples t-test for normally distributedFig. 1. Flow chart showing number of womecontinuous variables and chi squared tests for categorical variables
as appropriate. Odds ratios for the primary outcomes (having a
subsequent renal function test and development of CKD) weren included in analysis for each outcome.
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confidence intervals were calculated adjusting for age at first deliv-
ery, socio-economic status, smoking status, and body mass index
(BMI) at first pregnancy.
Time to CKD was examined using survival analysis techniques.
Kaplan-Meier plots and log-rank tests were employed as univariate
test for between group differences (pair-wise) in survival from
CKD. Cox’s proportional hazards models were employed to calcu-
late hazard ratios between groups adjusting for age at first deliv-
ery, socio-economic status, smoking status, and BMI.2.6. Ethics Statement
The North of Scotland Research Ethics Service confirmed that
formal ethical approval was not necessary to carry out analysis
on anonymized data. Permissions to carry out the study were
obtained from the steering committee of the Aberdeen Maternity
and Neonatal Databank, the NHS Grampian Caldicott guardian,
the Privacy Advisory Committee of NHS Scotland and the steering
committee for the Scottish Renal Registry.Table 1
Baseline (at time of delivery) characteristics by exposure status.
Characteristics Normotensive (n = 10,457) Gestational hyp
Age, mean (SD) years 25.3 (5.3) 25.0 (5.0)
Socio-economic status, n (%)
Most affluent I 1088 (10.4) 344 (9.6)
II 1694 (16.2) 559 (15.6)
III 4821 (46.1) 1727 (48.2)
IV 1955 (18.7) 659(18.4)
Least affluent V 899 (8.6) 290 (8.1)
Smoking status, n (%)
Non smoker 5887 (56.3) 2060 (57.5)
Ex smoker 398 (3.8) 129 (3.6)
Current smoker 4172(39.9) 1394 (38.9)
BMI, mean (SD) kg/m2 23.6 (3.6) 24.9 (4.1)
⁄p values represent a test for trend
Table 2
Logistic models with odds ratios for Chronic Kidney Disease; and Survival models with unad
mortality (all cause and cause specific).
N of events/N (%) Unadjusted
Odds ratio
95%CI for
Lower
CKD, n = 14,851
Normotensive 405/10457 (3.9) 1
Gestational Hypertension 188/3583 (5.2) 1.37 1.15
Pre-eclampsia 61/811 (7.5) 2.02 1.53
N of events/N (%) Unadjusted
Hazard ratio
95%CI for
Lower
CKD, n = 14,851
Normotensive 405/10457 (3.9) 1
Gestational Hypertension 188/3583 (5.2) 1.31 1.10
Pre-eclampsia 61/811 (7.5) 1.70 1.30
Hospital admissions for kidney
disease, n = 19,474
Normotensive 213/13989 (1.5) 1
Gestational Hypertension 82/4482 (1.8) 1.08 0.84
Pre-eclampsia 24/1003 (2.4) 1.42 0.93
All cause death, n = 25,692
Normotensive 562/18574 (3.0) 1
Gestational Hypertension 197/5857 (3.4) 0.99 0.84
Pre-eclampsia 60/1261 (4.8) 1.37 1.05
Cardiovascular deaths, n = 25,692
Normotensive 52/18574 (0.3) 1
Gestational Hypertension 29/5857 (0.5) 1.56 0.99
Pre-eclampsia 10/1261 (0.8) 2.53 1.28
Statistically significant p values are shown as bold.
a Adjusted for age at delivery, BMI, socio-economic status and smoking status.3. Results
A total of 14,851 women who had been linked to one or more of
the databases recording chronic kidney disease status and had
complete information regarding age, socio-economic class, smok-
ing and body mass index (BMI) were included in a multivariate
model. Of these, 811 had PE, 3583 had GH and 10,457 were nor-
motensive in their first pregnancy (see Fig. 1).3.1. Baseline comparisons
Table 1 presents comparison of baseline characteristics at the
time of first pregnancy by exposure status. Women with GH or
PE had a lower mean age when compared to normotensive women
at the time of delivery. Women with GH or PE also had significantly
higher mean BMI in comparison with NT women and were more
likely to have chronic hypertension, kidney disease, diabetes.
Those with chronic hypertension or CKD at baseline were excluded
from further analysis. A lower proportion of women with GH and
PE were in the higher socioeconomic classes when compared withertension (n = 3583) p value Pre-eclampsia (n = 811) p value
<0.001 24.8 (5.3) <0.001
<0.001 0.001
69(8.5)
125(15.4)
395 (48.7)
154 (19)
68 (8.4)
0.082 0.007
470(57.9)
21 (2.6)
320(39.5)
<0.001 25.3 (4.7) <0.001
justed and adjusted hazard ratios for Chronic Kidney Disease, hospital admissions and
Odds ratio p value Adjusted*
Odds ratio
95% CI Odds ratio p value
Upper Lower Upper
1 –
1.64 <0.001 1.36 1.14 1.63 0.001
2.67 <0.001 1.92 1.45 2.56 <0.001
Hazard ratio p value Adjusteda
Hazard ratio
95% CI Hazard ratio p value
Upper Lower Upper
– 1 –
1.55 0.002 1.14 0.96 1.36 0.139
2.23 <0.001 1.58 1.20 2.07 0.001
– 1 –
1.40 0.541 1.02 0.78 1.32 0.890
2.17 0.101 1.37 0.90 2.10 0.150
– 1 –
1.16 0.894 0.96 0.82 1.13 0.648
1.79 0.020 1.39 1.06 1.81 0.017
– 1 –
2.46 0.056 1.38 0.87 2.21 0.170
4.99 0.007 2.33 1.17 4.64 0.016
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women in the smoking categories between women with GH and
NT women but women with PE had significantly lower proportions
of women who had ever smoked (current and ex-smokers) com-
pared with NT women.
3.2. Probability of developing chronic kidney disease
Table 2 presents univariate and multivariate logistic regression
models for odds of developing subsequent CKD for women in the
three groups with complete information for all covariates in the
multivariate model (n = 14,851). Compared with normotensive
women, women with GH (OR = 1.37, 95%CI 1.15, 1.64) or PE
(OR = 2.02, 95%CI 1.53, 2.67) had statistically significantly higher
odds of developing subsequent CKD on univariate examination.
Adjusted odds ratios were 1.36 (95%CI 1.14, 1.63), and 1.92 (95%
CI 1.45, 2.56), for women with GH and PE respectively (adjusted
for age and year at delivery, BMI, socio-economic status and smok-
ing status). Again, in both analyses, there was evidence of a ‘‘dose
response” with OR greater in PE than GH.
3.3. Timing of onset of kidney function decline
The survival curves shown in Fig. 2 illustrate the time to devel-
opment of CKD for women in the different exposure groups as first
recorded in the RBD. Women were censored at death or, using the
more conservative approach (as compared to the previous model),
at last measurement if no further measurement of their kidney
function was recorded. The log rank p values represent pair-wise
comparisons between women with GH or PE and NT women. The
survival curves for women with GH or PE were significantly differ-
ent from that of NT women (p < 0.001 in each case).
Table 2 presents survival models with unadjusted and adjusted
hazard ratios for chronic kidney disease, hospital admissions for
kidney related conditions and all cause and cause specific mortal-
ity. Compared to normotensive women, women with PE had a
higher risk of developing CKD {AHR 1.58 (95% CI 1.20–2.07)} of
all cause mortality {AHR 1.39 (95% CI 1.06–1.81)} and death fromFig. 2. Kaplan-Meier plot showing survival (timcardiovascular disease {AHR 2.33 (95% CI 1.17–4.64)}. There was
no statistically significant difference in hospital admissions from
kidney disease. Women with GH did not differ in terms of CKD,
hospital admissions from kidney disease and all cause and cause
specific mortality from NT women.4. Discussion
On analysis of a large linked dataset with complete information
on co-variates, there appears to be a positive association between
gestational hypertension as well as preeclampsia with CKD both in
univariate as well as multivariate models. Further, women who
had gestational hypertension or preeclampsia were at risk of devel-
oping CKD earlier than normotensive women.
The study used high quality data on a large population based
cohort analysing approximately 2.5 million person years of follow
up with 811 women with preeclampsia . We have also used consis-
tent definitions of exposure and outcomes and incorporated the
broadest definition of CKD using both proteinuria and eGFR. The
linkage with different registers has enabled cross validation of
data. We acknowledge possible selection bias arising out of
restricting the study to women born before 1969. We also
acknowledge that different follow-up times for the different regis-
ters meant that some women’s outcome could not be adequately
classified. We have already acknowledged the uncertainty in the
timing of the first diagnosis of CKD for some women because the
biochemistry database only started in 1999. Furthermore, we had
no information on those women who remained unlinked to all reg-
isters, possibly excluding healthy women from our analysis.
Previous reports including a meta-analysis [6] have consistently
found associations between PE and CKD. The few studies that have
looked at GH and CKD have mostly reported positive associations
[13–15] with the notable exception of Gordin [16], who did not
find an increased risk of diabetic nephropathy in women with ges-
tational hypertension. There was considerable variation in the def-
inition of GH, PE and CKD in the literature. Most studies have used
microalbuminuria as the outcome measure, both as continuous as
well as a dichotomous variable. There were less consistentLog rank test:
N vs. GH: p < 0.001
N vs. PE: p < 0.001
e to CKD) curves for three study groups.
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the urine (proteinuria: >300 mg/24 h of protein detected in urine),
abnormal biochemistry blood tests (elevated creatinine or reduced
glomerular filtration rate (GFR)), abnormal renal biopsy or end
stage renal disease (ESRD) [7–9,13] . The largest, and most recently
published study [9], used record linkage of the Norwegian Birth
and Renal Registries to study the association of PE with Renal
Replacement Therapy (RRT). They found that PE in the first preg-
nancy was associated with an increased relative risk for RRT of
4.7 (95% CI 3.6, 6.1). The relative rarity of RRT meant that even a
large population based study like this could only identify 477
cases, assessing only the severe end of the spectrum. McDonald’s
meta-analysis [6], identified only 273 patients with preeclampsia
and less than 100 events of microalbuminuria across a total of 7
cohort studies. In contrast to the existing literature, our findings
suggest that the increase in the risk of developing milder CKD in
women with hypertensive disorders of pregnancy is likely to be
small. In support of this, Jacquemyn [17] did not find an association
between HELLP syndrome and long term renal complications.
5. Conclusions
Our analyses showed a statistically significantly increased rela-
tive risk of CKD in women with GH and PE compared to normoten-
sive women with a possible ‘dose response effect’. However the
absolute risk of CKD in GH and PE was very low (0.7% and 1.3% over
2.5 million person years of follow up). Therefore, the study demon-
strates an effect, a biological pathway whereby GH and PE affect
renal function in the longer term but the absolute risk of this hap-
pening is very low and therefore is probably not of sufficient clin-
ical importance to warrant any intervention or screening. If a
hypothetical intervention was put in place that reduced CKD by
50% in women with PE then the numbers needed to treat (NNT)
to prevent one CKD event would be around 150 (Inverse of the
absolute risk difference). Similarly, for GH, the NNT would be
approximately 285 women with GH. CKD occurs slightly earlier
in those with GH and PE, but our study had long follow up times
and large numbers of participants resulting in statistically signifi-
cant effects (type 1 error) which is of interest in terms of mecha-
nisms of disease occurrence, but probably of small clinical
relevance.
Currently women with GH and PE are reviewed within
2 months postpartum to ensure that hypertension and proteinuria
have resolved, but no specific advice is given regarding long term
follow up of renal function [18]. There appears to be a small but
significant increased risk of CKD in women with preeclampsia. This
implies that alongside managing risk of cardiovascular disease in
women with PE and GH, there is also a need to consider long term
kidney function. The same lifestyle and risk factor modifications
should apply – healthy diet, physical activity, maintaining healthy
weight, smoking cessation, cholesterol reduction and blood pres-
sure management.
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